Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...

The technical picture worsened for Eli Lilly stock in December as it completed a pattern known as a “Death Cross”. This ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

AnalytiXIN has launched a consortium designed to give Indiana researchers better access to health care data—potentially ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Eli Lilly CEO said he believed the company could find “significant common cause” with the Trump administration, even if there ...

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...